ArticleCancer gene therapy2002
Selective killing of cancer cells based on translational control of a suicide gene.
Article in Cancer gene therapy, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 35 citations in OpenAlex.
- The Eukaryotic Translation Initiation Factor 4E (eIF4E) as a Therapeutic Target for Cancer.Advances in protein chemistry and structural biology · 2015Review
- Targeted polymeric nanoparticles for cancer gene therapy.Journal of drug targeting · 2015Review
- Construction of a novel vector expressing the fusion suicide gene yCDglyTK and hTERT-shRNA and its antitumor effects.Experimental and therapeutic medicine · 2012Article
- Fibroblast growth factor and ornithine decarboxylase 5'UTRs enable preferential expression in human prostate cancer cells and in prostate tumors of PTEN(-/-) transgenic mice.Cancer gene therapy · 2012Article
- A programmable NOR-based device for transcription profile analysis.Scientific reports · 2012Article
- Development of chimeric gene regulators for cancer-specific gene therapy with both transcriptional and translational targeting.Molecular biotechnology · 2010Article
- eIF4E: new family members, new binding partners, new roles.The Journal of biological chemistry · 2009Review
- Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies.Oncogene · 2007Review
- Targeting and killing of prostate cancer cells using lentiviral constructs containing a sequence recognized by translation factor eIF4E and a prostate-specific promoter.Cancer gene therapy · 2006Article
- The antiviral drug ribavirin does not mimic the 7-methylguanosine moiety of the mRNA cap structure in vitro.RNA (New York, N.Y.) · 2005Article
- Review
- Does phosphorylation of the cap-binding protein eIF4E play a role in translation initiation?European journal of biochemistry · 2002Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The translation initiation factor, eIF4E, is commonly overexpressed in solid tumors. This elevation allows for efficient translation of mRNA that are normally repressed by their 5' untranslated region, many of which encode growth-promoting proteins. This property was exploited to modulate the synthesis of HTK at the translational level to selectively kill cancer cells. Various breast cancer cell lines can efficiently synthesize HTK from the translationally regulated mRNA, whereas normal cells cannot. Accordingly, only cancer cells were killed at low concentrations of ganciclovir. By altering the expression of eIF4E, it was possible to modulate the sensitivity of various cell lines to ganciclovir.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.